Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2017-07-14 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
八届三十四次董事会决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a board meeting of Kunming Pharmaceutical Group Co., Ltd. It details specific board decisions such as the unlocking of restricted stock incentives and approval of additional budget for the medical department. The text includes voting results and references to company governance procedures. There is no financial report, audit, or earnings data presented. The document is clearly a Board/Management Information announcement about board resolutions and internal decisions, not a full report or regulatory filing. Therefore, the appropriate classification is 'MANG' for Board/Management Information.
2017-07-14 Chinese
独立董事关于公司2016年授予股权激励所涉限制性股票解锁条件成就的独立意见
Regulatory Filings Classification · 90% confidence The document is an independent opinion from the independent directors regarding the fulfillment of conditions for unlocking restricted shares under a 2016 equity incentive plan. It references regulatory compliance, company law, securities law, and stock exchange listing rules. The content focuses on the verification of conditions for stock incentive unlocking rather than presenting financial statements or audit results. The document length is short (1046 characters) and it is a formal opinion related to corporate governance and compliance with incentive plan conditions. It does not contain financial data or audit results, nor is it an announcement of voting results or a general regulatory filing. The best fitting category is Regulatory Filings (RNS) as it is a compliance-related formal statement that does not fit other specific categories like Audit Report or Management Report.
2017-07-14 Chinese
八届十八次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a short announcement of a resolution passed by the supervisory board of Kunming Pharmaceutical Group Co., Ltd. It reports the approval of a proposal related to the unlocking of stock granted under a 2016 equity incentive plan. The document is brief (448 characters) and serves as a formal notice of a board decision rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a full report like an Annual Report or Interim Report, nor is it a call transcript or earnings release. The content fits best with a Regulatory Filing (RNS) as it is a formal regulatory announcement of a board resolution without extensive financial or operational detail.
2017-07-14 Chinese
关于2017年限制性股票激励计划所涉以集中竞价交易方式回购股份的回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share repurchase program related to a 2017 restricted stock incentive plan. It details the number of shares repurchased, prices, and total funds used. This is a report of the company buying back its own shares, which fits the definition of a Transaction in Own Shares (POS). The document is short and focused solely on the repurchase progress, not a full financial report or other type of filing.
2017-07-14 Chinese
北京德恒（昆明）律师事务所关于昆药集团股份有限公司2016年授予股权激励股票解锁事宜的法律意见
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the unlocking of restricted stock incentives granted by Kunming Pharmaceutical Group Co., Ltd. in 2016. It references compliance with Chinese company law, securities law, and regulations from the China Securities Regulatory Commission. The document details the conditions for unlocking restricted stock, the procedures the company has followed, and concludes that the unlocking conditions have been met and legal procedures complied with. It is a standalone legal opinion related to a specific corporate action (stock incentive unlocking), not a full financial report, earnings release, or management discussion. It does not contain financial statements or quarterly/yearly financial results. It is also not an announcement of a report publication but a substantive legal opinion document. Therefore, it fits best under the category of Legal Proceedings Report (LTR), as it deals with legal compliance and regulatory matters related to stock incentives.
2017-07-14 Chinese
董事会关于2016年授予股权激励所涉限制性股票解锁条件成就的说明
Regulatory Filings Classification · 95% confidence The document is a statement from the board of directors regarding the fulfillment of conditions for unlocking restricted stock under a 2016 equity incentive plan. It references company law, securities law, and stock exchange listing rules, and details conditions related to audit opinions, regulatory penalties, and compliance with incentive plan rules. The document is a formal explanation or announcement about the status of stock incentive unlocking conditions, not a full financial report or audit report. It is not a report publication announcement since it contains substantive content about the unlocking conditions. It is not related to management changes, voting results, or legal proceedings. The content fits best under Regulatory Filings (RNS) as it is a regulatory announcement about compliance with stock incentive plan conditions.
2017-07-14 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.